Stock 300630 HAINAN POLY PHARM. CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hainan Poly Pharm. Co., Ltd

Equities

300630

CNE100002N10

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
12.35 CNY -18.75% Intraday chart for Hainan Poly Pharm. Co., Ltd -15.81% -45.40%
04-08 Hainan Poly Pharm Gets Nod to Market Voriconazole Injection in Sweden MT
04-04 Hainan Poly Pharm Gets Nod to Market Skin Infection Drug in Germany MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 8,071 15,563 18,305 24,051 10,716 5,539 5,539 -
Enterprise Value (EV) 1 8,071 15,563 18,305 24,051 10,716 5,539 5,539 5,539
P/E ratio 44.5 x 51.5 x 44.6 x 57.9 x 27.4 x 11.6 x 9.96 x 8.61 x
Yield 0.48% 0.39% - - - 0.65% 0.81% 0.89%
Capitalization / Revenue 12.9 x 16.4 x 15.4 x 15.9 x 5.93 x 2.7 x 2.33 x 2 x
EV / Revenue 12.9 x 16.4 x 15.4 x 15.9 x 5.93 x 2.7 x 2.33 x 2 x
EV / EBITDA - - - 44.3 x 19.5 x 8.04 x 6.68 x 5.66 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book 9.14 x 13.6 x - 10 x 4.01 x 1.68 x 1.45 x 1.26 x
Nbr of stocks (in thousands) 420,988 420,988 436,989 436,980 434,540 448,542 448,542 -
Reference price 2 19.17 36.97 41.89 55.04 24.66 12.35 12.35 12.35
Announcement Date 19-02-26 20-02-26 21-04-23 22-04-13 23-04-24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 623.9 950.1 1,189 1,509 1,806 2,051 2,377 2,766
EBITDA 1 - - - 542.9 550.5 689.4 828.9 979
EBIT 1 209.9 333.5 457.8 468.1 439.5 532.9 627.4 733.9
Operating Margin 33.64% 35.1% 38.52% 31.02% 24.33% 25.98% 26.39% 26.53%
Earnings before Tax (EBT) 1 209.9 334.2 454.2 467.5 438.9 504.8 589 688
Net income 1 181.4 301.1 407.5 416.6 420.6 472.8 550.3 646
Net margin 29.08% 31.7% 34.28% 27.61% 23.29% 23.06% 23.15% 23.35%
EPS 2 0.4308 0.7179 0.9400 0.9500 0.9000 1.065 1.240 1.435
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 0.0914 0.1436 - - - 0.0800 0.1000 0.1100
Announcement Date 19-02-26 20-02-26 21-04-23 22-04-13 23-04-24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) 22.7% 29.7% 24% 17.9% 15.6% 14.5% 14.5% 14.8%
ROA (Net income/ Total Assets) - - 17.1% - - 6.33% 6.33% 6.38%
Assets 1 - - 2,388 - - 7,470 8,694 10,125
Book Value Per Share 2 2.100 2.720 - 5.500 6.150 7.360 8.510 9.820
Cash Flow per Share 2 0.2300 0.5100 0.7600 0.3600 1.220 0.6900 1.440 1.630
Capex 1 252 402 836 803 1,037 499 453 432
Capex / Sales 40.39% 42.31% 70.37% 53.25% 57.4% 24.31% 19.03% 15.6%
Announcement Date 19-02-26 20-02-26 21-04-23 22-04-13 23-04-24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hainan Poly Pharm. Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.35
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HAINAN POLY PHARM. CO., LTD Stock Hainan Poly Pharm. Co., Ltd
-45.40% 765M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300630 Stock
  4. Financials Hainan Poly Pharm. Co., Ltd